The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

Back to Search
Print
Bookmark Trial

NCT00163059

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Wichita, Kansas, 67214-2878, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Depressive Disorder, Major
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Primary DSM-IV diagnosis of MDD

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects with evidence or history of clinically significant hematological, renal,
endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,
neurologic, or allergic disease (including drug allergies, but excluding untreated,
asymptomatic, seasonal allergies at time of dosing).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Depressive Disorder, MajorThe Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
NCT00163059
  1. Wichita, Kansas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Depressive Disorder, MajorStudy Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder
NCT00300378
  1. Rijeka,
  2. Split,
  3. Zagreb,
  4. Tallinn,
  5. Tartu,
  6. Tartu,
  7. Espoo,
  8. Helsinki,
  9. Helsinki,
  10. Helsinki,
  11. Joensuu,
  12. Kuopio,
  13. Oulu,
  14. Rauma,
  15. Salo,
  16. Turku,
  17. Caen,
  18. Dole,
  19. Douai,
  20. Mulhouse,
  21. Orvault,
  22. Rennes,
  23. Tours,
  24. Jelgava,
  25. Liepaja,
  26. Riga,
  27. Strenci,
  28. Kaunas,
  29. Klaipeda,
  30. Vilnius,
  31. Lubiaz,
  32. Tuszyn,
  33. Zuromin,
  34. Bucuresti,
  35. Bucuresti,
  36. Craiova,
  37. Bojnice,
  38. Bratislava,
  39. Rimavska Sobota,
  40. Bloemfontein,
  41. Cape Town,
  42. Durban,
  43. Pretoria,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
Official Title  ICMJE A Randomized, Double-Blinded, Placebo-Controlled Trial To Assess The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With Treatment Refractory Major Depressive Disorder
Brief Summary To determine if the NMDA antagonist, CP-101,606, is effective for depression
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Condition  ICMJE Depressive Disorder, Major
Intervention  ICMJE Drug: NMDA Antagonist, CP-101,606 (traxoprodil)
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: September 9, 2005)		30
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE December 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Primary DSM-IV diagnosis of MDD

Exclusion Criteria:

  • Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00163059
Other Study ID Numbers  ICMJE A1611006
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP